| B-Cell Neoplasm altered in cohorts of …ALTERED_INderived200 of 377show all (up to 200) |
|---|
| ← altered in cohorts of | MTRNR2L6 23 / 50 cases (46 %) · ssm · TCGA-DLBC · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TUBB8B 23 / 50 cases (46 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGHV2-70 437 / 961 cases (45 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ASPM 22 / 50 cases (44 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DSEL 22 / 50 cases (44 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR149 22 / 50 cases (44 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMA1 22 / 50 cases (44 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRSS1 22 / 50 cases (44 %) · ssm · CGCI-HTMCP-DLBCL · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PRSS2 22 / 50 cases (44 %) · ssm · CGCI-HTMCP-DLBCL · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCA13 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADCYAP1 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AHR 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASXL3 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CETN1 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLUL1 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COLEC12 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENOSF1 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FOXD4L5 21 / 50 cases (42 %) · ssm · CGCI-HTMCP-DLBCL · largest of 2 cohorts | — | — | Diffuse Large B-Cell Lymphoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | POTEC 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SALL3 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THOC1 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TYMS 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP14 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YES1 21 / 50 cases (42 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDX3X 124 / 297 cases (42 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ACTB 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ANKRD20A3P 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ANKRD30B 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF26 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARL8A 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP9B 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | B3GAT1 20 / 50 cases (40 %) · ssm · CGCI-HTMCP-DLBCL | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL9L 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BRINP3 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CACNA1S 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CBLN2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CBWD5 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CFH 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CFHR2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CFHR3 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHIT1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CPB1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTDP1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSE 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DIPK1C 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FOXD4L4 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GLB1L2 20 / 50 cases (40 %) · ssm · CGCI-HTMCP-DLBCL | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HLA-DRB1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HLA-DRB5 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HLTF 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HPS3 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSBP1L1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF10 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNG2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC30 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRN3 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAGI2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | METTL4 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC20 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYOG 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYOM1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NETO1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NFATC1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OSBPL10 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PARD6G 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PKP1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLCH1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PPFIA4 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMG2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTPN2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBFA 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RFC4 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RGS1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RTP2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RTP4 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB10 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINB7 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SIAH2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC66A2 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPDYE17 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SST 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TPR 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TSHZ1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBBX 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZIC1 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF658 20 / 50 cases (40 %) · ssm · TCGA-DLBC | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGLV3-1 364 / 961 cases (38 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SHCBP1 73 / 263 cases (28 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS35 67 / 263 cases (25 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ORC6 66 / 263 cases (25 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TPTE 66 / 263 cases (25 %) · ssm · CGCI-BLGSP · largest of 3 cohorts | — | — | Burkitt Lymphoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | IGHV2-70D 238 / 961 cases (25 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KMT2D 247 / 1,001 cases (25 %) · ssm · dlbcl_duke_2017 · largest of 6 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 6 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KRAS 227 / 961 cases (24 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | MYLK3 62 / 263 cases (24 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CNTNAP3B 70 / 297 cases (24 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BCL7A 212 / 961 cases (22 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | IGLL5 211 / 961 cases (22 %) · ssm · MMRF-COMMPASS · largest of 5 cohorts | — | — | Multiple Myeloma | 5 | Observed | gdc | graph → |
| ← altered in cohorts of | C16orf87 56 / 263 cases (21 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LTB 186 / 961 cases (19 %) · ssm · MMRF-COMMPASS · largest of 2 cohorts | — | — | Multiple Myeloma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NRAS 183 / 961 cases (19 %) · ssm · MMRF-COMMPASS · largest of 3 cohorts | — | — | Multiple Myeloma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PTPRC 50 / 263 cases (19 %) · ssm · CGCI-BLGSP · largest of 2 cohorts | — | — | Burkitt Lymphoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GARIN4 55 / 297 cases (19 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF280B 48 / 263 cases (18 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF280A 47 / 263 cases (18 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO11 53 / 297 cases (18 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | GGTLC2 46 / 263 cases (17 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAME 46 / 263 cases (17 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYD88 172 / 1,001 cases (17 %) · ssm · dlbcl_duke_2017 · largest of 5 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BTG1 67 / 396 cases (17 %) · ssm · mbn_msk_2024 · largest of 2 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | OR11H12 44 / 263 cases (17 %) · ssm · CGCI-BLGSP · largest of 2 cohorts | — | — | Burkitt Lymphoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GP6 49 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ATP6V1G3 43 / 263 cases (16 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF6 43 / 263 cases (16 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEB 123 / 755 cases (16 %) · ssm · mbn_mdacc_2013 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SF3B1 174 / 1,075 cases (16 %) · ssm · cll_broad_2022 · largest of 4 cohorts | — | — | Small Lymphocytic Lymphoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | AKAP10 47 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MAP3K9 47 / 297 cases (16 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CD84 40 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENSA 40 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MIR5195 143 / 961 cases (15 %) · ssm · MMRF-COMMPASS | — | — | Multiple Myeloma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAMTSL4 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf56 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD48 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDC42SE1 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABPB2 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLPH3L 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MLLT11 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TARS2 39 / 263 cases (15 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIM1 147 / 1,001 cases (15 %) · ssm · dlbcl_duke_2017 · largest of 5 cohorts | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANXA9 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARNT 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BNIPL 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSK 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTSS 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTXND2 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECM1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM243B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HORMAD1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNE1B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MCL1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MINDY1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRUNE1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF1 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF7 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMIM11B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMIM34B 38 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FRG2C 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SMPD1 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPATA31A6 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF701 42 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CERS2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPT2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYSMD1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPRD2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCNM1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA6C 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SETDB1 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMOD4 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP8L2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VANGL2 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS72 37 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HLA-A 55 / 396 cases (14 %) · ssm · mbn_msk_2024 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | L1TD1 41 / 297 cases (14 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FCRL4 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEK7 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIP5K1A 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 36 / 263 cases (14 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD79B 54 / 396 cases (14 %) · ssm · mbn_msk_2024 · largest of 3 cohorts | — | — | B-Cell Non-Hodgkin Lymphoma | 3 | Observed | cbioportal | graph → |
| ← altered in cohorts of | APH1A 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf54 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CA14 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CIART 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL2 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL3 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL5 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPS21 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCSTN 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NHLH1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINC1 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SYT11 35 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR52 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RABGAP1L 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RC3H1 34 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC4B 38 / 297 cases (13 %) · ssm · mbn_sfu_2023 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANP32E 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD5L 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COPA 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DARS2 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GON4L 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PGM5 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD4 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB37 33 / 263 cases (13 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APOA2 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCAF8 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJA2 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCER1G 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY9 32 / 263 cases (12 %) · ssm · CGCI-BLGSP | — | — | Burkitt Lymphoma | 1 | Observed | gdc | graph → |